NYSE:ANVS Annovis Bio (ANVS) Stock Price, News & Analysis → Claim Your Complimentary Bitcoin Reward (From Crypto Swap Profits) (Ad) Free ANVS Stock Alerts $11.86 -0.17 (-1.41%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$11.58▼$12.5850-Day Range$8.47▼$12.9352-Week Range$5.42▼$23.89Volume249,597 shsAverage Volume286,541 shsMarket Capitalization$125.48 millionP/E RatioN/ADividend YieldN/APrice Target$27.75 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Annovis Bio alerts: Email Address Annovis Bio MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside134.0% Upside$27.75 Price TargetShort InterestHealthy17.31% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.55Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($5.07) to ($3.49) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.45 out of 5 starsMedical Sector538th out of 938 stocksBiotechnology Industry8th out of 26 stocks 3.4 Analyst's Opinion Consensus RatingAnnovis Bio has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $27.75, Annovis Bio has a forecasted upside of 134.0% from its current price of $11.86.Amount of Analyst CoverageAnnovis Bio has only been the subject of 2 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted17.31% of the float of Annovis Bio has been sold short.Short Interest Ratio / Days to CoverAnnovis Bio has a short interest ratio ("days to cover") of 4.2.Change versus previous monthShort interest in Annovis Bio has recently decreased by 8.16%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAnnovis Bio does not currently pay a dividend.Dividend GrowthAnnovis Bio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ANVS. Previous Next 3.1 News and Social Media Coverage News SentimentAnnovis Bio has a news sentiment score of 0.55. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Annovis Bio this week, compared to 2 articles on an average week.Search Interest22 people have searched for ANVS on MarketBeat in the last 30 days. This is an increase of 22% compared to the previous 30 days.MarketBeat Follows10 people have added Annovis Bio to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Annovis Bio insiders have not sold or bought any company stock.Percentage Held by Insiders38.30% of the stock of Annovis Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 15.83% of the stock of Annovis Bio is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Annovis Bio are expected to grow in the coming year, from ($5.07) to ($3.49) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Annovis Bio is -2.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Annovis Bio is -2.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAnnovis Bio has a P/B Ratio of 3.42. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad WealthPress$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…Go here to watch the most recent trading workshop video at no charge. About Annovis Bio Stock (NYSE:ANVS)Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which is in Phase 3 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405 for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.Read More ANVS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ANVS Stock News HeadlinesMarch 24, 2024 | msn.comAnnovis Bio Nears Milestone in Alzheimer’s Treatment Study with Completion of Data CleaningMarch 23, 2024 | americanbankingnews.comAnnovis Bio (NYSE:ANVS) Stock Rating Reaffirmed by HC WainwrightMarch 29, 2024 | WealthPress (Ad)A lot of people are making this costly mistakeYou may have heard the saying “options are risky” … And, they can be. But only if you use them the way a lot of folks do. A lot of people think of BUYING speculative options when they talk about options. And BUYING low probability, speculative options is definitely risky… It’s how some folks leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. March 21, 2024 | marketwatch.comAnnovis Bio Shares Up 31% on Progress Toward Reporting Data From Alzheimer's StudyMarch 20, 2024 | marketwatch.comAnnovis Bio Completes Data Cleaning for Buntanetap StudyMarch 20, 2024 | finance.yahoo.comANVS Jul 2024 30.000 callMarch 20, 2024 | msn.comAnnovis to release efficacy data on Alzheimer's drug in AprilMarch 20, 2024 | globenewswire.comAnnovis Bio Provides Data Announcement Update for the Phase II/III Study of Buntanetap in Alzheimer's DiseaseMarch 29, 2024 | WealthPress (Ad)A lot of people are making this costly mistakeYou may have heard the saying “options are risky” … And, they can be. But only if you use them the way a lot of folks do. A lot of people think of BUYING speculative options when they talk about options. And BUYING low probability, speculative options is definitely risky… It’s how some folks leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. March 18, 2024 | finance.yahoo.comANVS Oct 2024 5.000 putMarch 18, 2024 | finance.yahoo.comANVS Apr 2024 20.000 callMarch 18, 2024 | msn.comAre Options Traders Betting on a Big Move in Annovis Bio (ANVS) Stock?March 15, 2024 | 247wallst.com$10 Biotech Stock Wall Street Says Will Be Up Over 200% This YearMarch 6, 2024 | investorplace.comSell Signal: 3 Stocks to Unload Before the Bubble BurstsMarch 4, 2024 | msn.comAnnovis Bio to Shed Light on Neurodegenerative Diseases at International ConferenceFebruary 29, 2024 | stockhouse.comAnnovis Bio Announces Participation in Forum Discussion at AD/PD(TM) 2024February 28, 2024 | msn.comBrookline Capital Downgrades Annovis Bio (ANVS)February 28, 2024 | markets.businessinsider.comMaintaining Hold on Annovis Bio Amid Phase 3 Parkinson’s Trial Concerns and Financial UncertaintiesFebruary 28, 2024 | msn.comAnnovis Bio falls after Brookline Capital downgrades on PD trial complicationsFebruary 27, 2024 | globenewswire.comAnnovis Bio Announces Participation in Forum Discussion at AD/PD™ 2024February 17, 2024 | investing.comAnnovis Bio Inc (ANVS)February 16, 2024 | msn.comAnnovis Bio Wraps Up Phase II/III Trial for Alzheimer's Drug BuntanetapFebruary 16, 2024 | markets.businessinsider.comBuy Rating Justified for Annovis Bio Amidst Promising Buntanetap Clinical Trials and Strong Commercial ProspectsFebruary 15, 2024 | finanznachrichten.deAnnovis Bio Inc.: Annovis Bio Announces Last Patient Last Visit in the Phase II/III Study of Buntanetap in Alzheimer's DiseaseFebruary 15, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Annovis Bio (ANVS), Alnylam Pharma (ALNY)February 15, 2024 | markets.businessinsider.comBuy Rating on Annovis Bio Amid Anticipated Positive Outcomes for Buntanetap in AD and PD TrialsFebruary 14, 2024 | globenewswire.comAnnovis Bio Announces Last Patient Last Visit in the Phase II/III Study of Buntanetap in Alzheimer's DiseaseSee More Headlines Receive ANVS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Annovis Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/08/2023Today3/29/2024Next Earnings (Estimated)4/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNYSE:ANVS CUSIPN/A CIK1477845 Webwww.annovisbio.com Phone610-727-3913FaxN/AEmployees5Year FoundedN/APrice Target and Rating Average Stock Price Target$27.75 High Stock Price Target$36.00 Low Stock Price Target$9.00 Potential Upside/Downside+134.0%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($4.27) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-25,330,000.00 Net MarginsN/A Pretax Margin-74,496.43% Return on Equity-195.55% Return on Assets-156.80% Debt Debt-to-Equity RatioN/A Current Ratio2.87 Quick Ratio2.87 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.47 per share Price / Book3.42Miscellaneous Outstanding Shares10,580,000Free Float6,528,000Market Cap$125.48 million OptionableOptionable Beta1.55 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesDr. Maria L. Maccecchini Ph.D. (Age 73)Founder, CEO, President & Executive Director Comp: $965.6kMr. Henry Hagopian III (Age 56)M.B.A., Chief Financial Officer Comp: $510.05kDr. Cheng Fang Ph.D.Senior Vice President of Research & DevelopmentMs. Eve M. Damiano M.S.RAC, Senior Vice President of Regulatory OperationsMs. Melissa GainesSenior Vice President of Clinical OperationsKey CompetitorsCitius PharmaceuticalsNASDAQ:CTXREmergent BioSolutionsNYSE:EBSKinnate BiopharmaNASDAQ:KNTENGM BiopharmaceuticalsNASDAQ:NGMSyros PharmaceuticalsNASDAQ:SYRSView All CompetitorsInstitutional OwnershipVanguard Group Inc.Bought 78,824 shares on 3/11/2024Ownership: 3.189%Vanguard Group Inc.Bought 78,824 shares on 2/15/2024Ownership: 3.189%GTS Securities LLCBought 11,500 shares on 2/15/2024Ownership: 0.000%Citadel Advisors LLCBought 2,300 shares on 2/15/2024Ownership: 0.000%Northern Trust CorpBought 18,868 shares on 2/13/2024Ownership: 0.275%View All Institutional Transactions ANVS Stock Analysis - Frequently Asked Questions Should I buy or sell Annovis Bio stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Annovis Bio in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ANVS shares. View ANVS analyst ratings or view top-rated stocks. What is Annovis Bio's stock price target for 2024? 4 analysts have issued 1 year price objectives for Annovis Bio's stock. Their ANVS share price targets range from $9.00 to $36.00. On average, they predict the company's stock price to reach $27.75 in the next year. This suggests a possible upside of 134.0% from the stock's current price. View analysts price targets for ANVS or view top-rated stocks among Wall Street analysts. How have ANVS shares performed in 2024? Annovis Bio's stock was trading at $18.70 at the beginning of the year. Since then, ANVS shares have decreased by 36.6% and is now trading at $11.86. View the best growth stocks for 2024 here. Are investors shorting Annovis Bio? Annovis Bio saw a decline in short interest in March. As of March 15th, there was short interest totaling 1,350,000 shares, a decline of 8.2% from the February 29th total of 1,470,000 shares. Based on an average trading volume of 318,600 shares, the short-interest ratio is presently 4.2 days. Approximately 17.3% of the company's shares are sold short. View Annovis Bio's Short Interest. When is Annovis Bio's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, April 1st 2024. View our ANVS earnings forecast. How were Annovis Bio's earnings last quarter? Annovis Bio, Inc. (NYSE:ANVS) announced its quarterly earnings results on Wednesday, November, 8th. The company reported ($1.63) EPS for the quarter, missing the consensus estimate of ($1.10) by $0.53. What other stocks do shareholders of Annovis Bio own? Based on aggregate information from My MarketBeat watchlists, some companies that other Annovis Bio investors own include ADMA Biologics (ADMA), Bionano Genomics (BNGO), KushCo (KSHB), Matinas BioPharma (MTNB), Zosano Pharma (ZSAN), Auxly Cannabis Group (CBWTF), Novan (NOVN), Sorrento Therapeutics (SRNE), CNBX Pharmaceuticals (CNBX) and Enerplus (ERF). When did Annovis Bio IPO? Annovis Bio (ANVS) raised $10 million in an IPO on Wednesday, January 29th 2020. The company issued 1,400,000 shares at $6.00-$8.00 per share. ThinkEquity (a division of Fordham Financial Management, Inc. ) acted as the underwriter for the IPO. Who are Annovis Bio's major shareholders? Annovis Bio's stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (3.19%), Vanguard Group Inc. (3.19%), Northern Trust Corp (0.27%), Merit Financial Group LLC (0.21%), GTS Securities LLC (0.00%) and Dimensional Fund Advisors LP (0.10%). Insiders that own company stock include Claudine Bruck, Maria-Luisa Maccecchini and Reid Mccarthy. View institutional ownership trends. How do I buy shares of Annovis Bio? Shares of ANVS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSE:ANVS) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 Media“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyOnly a fool would buy Nvidia today… Porter & CompanyMost important medical advance in 100 yearsThe Oxford Club Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Annovis Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.